January 26, 2015 4:49 PM ET

Pharmaceuticals

Company Overview of Novartis Pharmaceuticals Corporation

Company Overview

Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for patients in the United States. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, and skin diseases and conditions. The company also provides patient assistance programs. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1997. The company was incorporated in 1968 and is based in Ea...

One Health Plaza

East Hanover, NJ 07936-1080

United States

Founded in 1968

Phone:

973-781-8300

Fax:

973-781-8265

Key Executives for Novartis Pharmaceuticals Corporation

President
Chief Financial & Administrative Officer and Vice President
Chief Compliance Officer
Vice President
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2014.

Novartis Pharmaceuticals Corporation Key Developments

Novartis Pharmaceuticals to Lay Off about 200 People from its Primary Care Force

Novartis Pharmaceuticals will lay off about 200 people from its primary care force as it shifts emphasis to cardiovascular disease. A notice of the impending layoffs, listed effective February 16, in East Hanover, appeared on state Department of Labor and Workforce Development's website late last week.

Sandoz Unveils Generic Version of Cystic Fibrosis Medication in US

Sandoz announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI, currently marketed by Novartis Pharmaceuticals Corporation. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa.

Novartis Pharmaceuticals Announces Executive Appointments

Novartis AG announced that Vas Narasimhan is appointed Global Head of Development, Novartis Pharmaceuticals, effective August 1, 2014. Narasimhan joined Novartis in 2005 and will succeed Tim Wright, who has decided to pursue opportunities outside the company and to spend more time with his family. Narasimhan has worked within the Pharmaceuticals and Vaccines businesses and has held the role of Global Head, Development, Novartis Vaccines. In addition, Eric Cornut is appointed Chief Ethics, Compliance and Policy Officer, effective August 1, 2014. Cornut will lead the Integrity & Compliance and Public Affairs functions at Novartis. He has held numerous leadership positions at Novartis, exposing him to many different stakeholder groups. His role as the Chief Commercial Officer at Novartis Pharmaceuticals, as well as previous positions at regional and country levels, have positioned him well to work in partnership with external stakeholders.

Similar Private Companies By Industry

Company Name Region
Tansna Therapeutics, Inc. United States
Advanced Influenza Technologies, Inc. United States
Janson Beckett Cosmeceuticals, Inc United States
Wockhardt USA, Inc. United States
InnoPharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novartis Pharmaceuticals Corporation, please visit www.pharma.us.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.